Max Rosett Sells 60,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CFO Max Rosett sold 60,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $18.23, for a total value of $1,093,800.00. Following the completion of the sale, the chief financial officer owned 54,037 shares of the company’s stock, valued at approximately $985,094.51. This represents a 52.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Max Rosett also recently made the following trade(s):

• On Thursday, April 2nd, Max Rosett sold 65,000 shares of Immunome stock. The stock was sold at an average price of $21.92, for a total value of $1,424,800.00.

Immunome Stock Performance

IMNM stock opened at $18.74 on Friday. The stock’s 50 day simple moving average is $21.50 and its 200 day simple moving average is $21.71. The company has a market cap of $2.12 billion, a P/E ratio of -7.87 and a beta of 2.04. Immunome, Inc. has a fifty-two week low of $7.96 and a fifty-two week high of $27.65.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Equities analysts predict that Immunome, Inc. will post -2.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

IMNM has been the topic of several research reports. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Craig Hallum lifted their price objective on shares of Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Immunome in a research report on Wednesday, May 13th. Truist Financial upped their target price on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Finally, Stephens dropped their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $33.17.

Hedge Funds Weigh In On Immunome

Hedge funds have recently bought and sold shares of the company. KBC Group NV purchased a new stake in shares of Immunome in the first quarter valued at about $60,000. Strs Ohio purchased a new position in Immunome during the fourth quarter worth about $64,000. Assetmark Inc. purchased a new position in Immunome during the third quarter worth about $39,000. Aster Capital Management DIFC Ltd bought a new stake in Immunome in the 4th quarter worth about $121,000. Finally, BIT Capital GmbH bought a new stake in Immunome in the 3rd quarter worth about $69,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.